.After antibody-drug conjugate (ADC) specialist Seagen was marketed to Pfizer in 2014 for an immense...
.On the heels of a stage 3 succeed that fell short to wow entrepreneurs, Ironwood Pharmaceuticals is...
.Do not cease Monte Rosa Rehabs currently. The Boston-based biotech is actually enjoying after autho...
.Invite to this week's Chutes & Ladders, our roundup of significant management hirings, firings a...
.Celebrating his provider's upsized going public (IPO), Septerna chief executive officer Jeffrey Fin...
.AbbVie has actually gone back to the resource of its antipsychotic powerhouse Vraylar trying to fin...
.GenSight Biologics is actually weeks off of running out of funds. Once again. The biotech simply ha...
.Monopar Therapeutics is actually recouping a drug from the dump of AstraZeneca's unusual disease pi...
.With new information out on Arcus Biosciences' experimental HIF-2a inhibitor, one group of experts ...
.After creating a genetics treatment partnership with Dyno Therapeutics in 2020, Roche is back for a...
.Lundbeck is reducing the book worth of its own $250 thousand Abide Therapeutics buyout in reaction ...
.The assimilation of real-world records (RWD) right into procedure usefulness as well as web site as...
.At this year's Strong Biotech Summit in Boston, our company caught up with innovators in the biotec...
.Merck & Co. is actually putting down $30 thousand ahead of time to buy Yale spinout Modifi Biosc...
.Alpha-9 Oncology has elevated a $175 thousand collection C round to bankroll its clinical-stage rad...
.Eye medication maker Ocuphire Pharma is acquiring genetics treatment designer Opus Genetics in an a...
.Roche's chronic coughing plan has faltered to a halt. The drugmaker, which axed the program after t...
.Gilead Sciences and also Merck & Co. have guided their once-weekly HIV combo treatment past an a...
.Lykos Therapeutics might have dropped three-quarters of its staff back the FDA's rejection of its M...
.Septerna may be yet to divulge "any kind of significant scientific records," yet the biotech plainl...